Replies to post #83408 on Biotech Values

[DewDiligence]

VVUS on the IP issue: I have posted sometime ago at SI that JNJ holds a method-of-use patent covering the use of topiramate (Topamax) in obesity and there are overlapping claims with Qnexa patentm so I believe JNJ has a ground to sue.

Since this patent isn’t worth much in practice, VVUS doesn’t have much to lose even if JNJ does decide to sue.